LumiraDx (LMDX) Stock Forecast, Price Target & Predictions
LMDX Stock Forecast
LumiraDx stock forecast is as follows: an average price target of $1.50 (represents a 9900.00% upside from LMDX’s last price of $0.01) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
LMDX Price Target
The average price target for LumiraDx (LMDX) is $1.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $1.50 to $1.50. This represents a potential 9900.00% upside from LMDX's last price of $0.01.
LMDX Analyst Ratings
According to 1 Wall Street analysts, LumiraDx's rating consensus is 'Buy'. The analyst rating breakdown for LMDX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
LumiraDx Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 07, 2023 | Andrew Cooper | Raymond James | $1.50 | $0.62 | 141.16% | 9900.00% |
The latest LumiraDx stock forecast, released on Apr 07, 2023 by Andrew Cooper from Raymond James, set a price target of $1.50, which represents a 141.16% increase from the stock price at the time of the forecast ($0.62), and a 9900.00% increase from LMDX last price ($0.01).
LumiraDx Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.01 | $0.01 | $0.01 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of LumiraDx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LumiraDx's last price of $0.01. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 07, 2023 | Raymond James | Outperform | Outperform | Hold |
| May 12, 2022 | Raymond James | Outperform | Outperform | Hold |
LumiraDx's last stock rating was published by Raymond James on Apr 07, 2023. The company gave LMDX a "Outperform" rating, the same as its previous rate.
LumiraDx Financial Forecast
LumiraDx Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $22.17M | $126.41M |
| Avg Forecast | $47.26M | $42.01M | $36.76M | $31.15M | $20.53M | $21.00M | $41.75M | $113.13M |
| High Forecast | $49.05M | $43.60M | $38.15M | $31.15M | $20.53M | $21.80M | $43.33M | $117.41M |
| Low Forecast | $45.73M | $40.65M | $35.57M | $31.15M | $20.53M | $20.33M | $40.40M | $109.47M |
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - |
| Surprise % | - | - | - | - | - | - | 0.53% | 1.12% |
LumiraDx's average Quarter revenue forecast for Jun 23 based on 1 analysts is $21.00M, with a low forecast of $20.33M, and a high forecast of $21.80M. LMDX's average Quarter revenue forecast represents a -5.27% decrease compared to the company's last Quarter revenue of $22.17M (Mar 23).
LumiraDx EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - |
| EBITDA | - | - | - | - | - | - | $-20.84M | $-17.62M |
| Avg Forecast | $-32.40M | $-28.80M | $-25.20M | $-21.36M | $-14.08M | $-14.40M | $-28.63M | $-77.57M |
| High Forecast | $-33.63M | $-29.89M | $-26.16M | $-21.36M | $-14.08M | $-14.95M | $-29.71M | $-80.50M |
| Low Forecast | $-31.36M | $-27.87M | $-24.39M | $-21.36M | $-14.08M | $-13.94M | $-27.70M | $-75.06M |
| Surprise % | - | - | - | - | - | - | 0.73% | 0.23% |
undefined analysts predict LMDX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LumiraDx's previous annual EBITDA (undefined) of $NaN.
LumiraDx Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - |
| Net Income | - | - | - | - | - | - | $-44.12M | $-56.17M |
| Avg Forecast | $490.24M | $426.77M | $501.12M | $-19.13M | $-35.08M | $-47.83M | $-60.59M | $-19.13M |
| High Forecast | $392.19M | $341.42M | $400.89M | $-19.13M | $-35.08M | $-38.27M | $-48.47M | $-15.31M |
| Low Forecast | $588.28M | $512.13M | $601.34M | $-19.13M | $-35.08M | $-57.40M | $-72.70M | $-22.96M |
| Surprise % | - | - | - | - | - | - | 0.73% | 2.94% |
LumiraDx's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LMDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
LumiraDx SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - |
| SG&A | - | - | - | - | - | - | $25.98M | $40.16M |
| Avg Forecast | $26.10M | $23.20M | $20.30M | $17.20M | $11.34M | $11.60M | $23.06M | $62.48M |
| High Forecast | $27.09M | $24.08M | $21.07M | $17.20M | $11.34M | $12.04M | $23.93M | $64.84M |
| Low Forecast | $25.26M | $22.45M | $19.64M | $17.20M | $11.34M | $11.23M | $22.31M | $60.46M |
| Surprise % | - | - | - | - | - | - | 1.13% | 0.64% |
LumiraDx's average Quarter SG&A projection for Jun 23 is $11.60M, based on 1 Wall Street analysts, with a range of $11.23M to $12.04M. The forecast indicates a -55.34% fall compared to LMDX last annual SG&A of $25.98M (Mar 23).
LumiraDx EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | - |
| EPS | - | - | - | - | - | - | $-0.14 | $-0.22 |
| Avg Forecast | $1.54 | $1.34 | $1.57 | $-0.06 | $-0.11 | $-0.15 | $-0.19 | $-0.06 |
| High Forecast | $1.23 | $1.07 | $1.26 | $-0.06 | $-0.11 | $-0.12 | $-0.15 | $-0.05 |
| Low Forecast | $1.84 | $1.61 | $1.89 | $-0.06 | $-0.11 | $-0.18 | $-0.23 | $-0.07 |
| Surprise % | - | - | - | - | - | - | 0.74% | 3.67% |
According to undefined Wall Street analysts, LumiraDx's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LMDX previous annual EPS of $NaN (undefined).
LumiraDx Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LMDX | LumiraDx | $0.02 | $1.50 | 7400.00% | Buy |
| DRIO | DarioHealth | $0.95 | $10.75 | 1031.58% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $2.96 | $6.00 | 102.70% | Buy |
| BDSX | Biodesix | $1.77 | $3.00 | 69.49% | Buy |
| SHC | Sotera Health Company | $16.80 | $16.93 | 0.77% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
LMDX Forecast FAQ
Is LumiraDx a good buy?
Yes, according to 1 Wall Street analysts, LumiraDx (LMDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of LMDX's total ratings.
What is LMDX's price target?
LumiraDx (LMDX) average price target is $1.5 with a range of $1.5 to $1.5, implying a 9900.00% from its last price of $0.015. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will LumiraDx stock go up soon?
According to Wall Street analysts' prediction for LMDX stock, the company can go up by 9900.00% (from the last price of $0.015 to the average price target of $1.5), up by 9900.00% based on the highest stock price target, and up by 9900.00% based on the lowest stock price target.
Can LumiraDx stock reach $0?
LMDX's average twelve months analyst stock price target of $1.5 supports the claim that LumiraDx can reach $0 in the near future.
What are LumiraDx's analysts' financial forecasts?
LMDX's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $114.43M (high $116.81M, low $112.41M), average EBITDA is $-78.462M (high $-80.089M, low $-77.072M), average net income is $-163M (high $-141M, low $-184M), average SG&A $63.2M (high $64.51M, low $62.08M), and average EPS is $-0.51 (high $-0.442, low $-0.578).
Did the LMDX's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Mar 2023), LumiraDx's revenue was $22.17M, missing the average analysts' forecast of $41.75M by -46.89%. The company's EBITDA was $-20.837M, missing the average prediction of $-28.626M by -27.21%. LumiraDx's net income was $-44.123M, missing the average estimation of $-60.587M by -27.17%. The company's SG&A was $25.98M, beating the average forecast of $23.06M by 12.66%. Lastly, the company's EPS was $-0.14, missing the average prediction of $-0.19 by -26.32%